Methods for treating HCV

US8685984B2 · kind B2 · utility

Assignee

• Abb Vie Inc. · US

Inventors

• Barry M. Bernstein · Mequon, US
• Rajeev M. Menon · Buffalo Grove, US
• Amit Khatri · Waukegan, US
• Sven Mensing · Mannheim, DE
• Sandeep Dutta · Waukegan, US
• Daniel E. Cohen · Wilmette, US
• Scott C. Brun · Libertyville, US
• Walid M. Awni · Libertyville, US
• Emily O. Dumas · Libertyville, US
• Cheri E. Klein · Northbrook, US
• Thomas J. Podsadecki · Chicago, US

Key dates

• Filing date: Jul 5, 2013
• Grant date: Apr 1, 2014
• Expiry date: Jul 5, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G16B5/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).